Internal Medicine, Medical Oncology · Gadsden, AL
NPI
1609890474
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
705 Goodyear Ave
Gadsden, AL, 35903
Phone (256) 492-0375
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.4M
229,655 services
Medicare patients, 2024
692
Average age 74
Drug cost, 2024
$10.1M
4,155 prescriptions
Company payments, 2025
$363
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elquis M Castillo was code J9271 (injection, pembrolizumab, 1 mg), 41,800 times for 35 patients. In total Elquis M Castillo billed 229,655 services in 117 codes, and Medicare paid $5.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 41,800 | 35 | $44.50 | $1.9M |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 17,100 | 124 | $15.69 | $268K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 13,224 | 15 | $36.81 | $487K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 12,750 | 14 | $0.25 | $3,165 |
| J0897 Injection, denosumab, 1 mg | Office | 9,300 | 35 | $20.53 | $191K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,520 | 25 | $6.40 | $48K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,023 | 58 | $0.09 | $436 |
| 85025 Blood Count | Office | 2,876 | 547 | $7.60 | $22K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,370 | 44 | $0.71 | $1,685 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,048 | 27 | $0.07 | $149 |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,980 | 12 | $6.18 | $12K |
| 36415 Venipuncture Blood Collection | Office | 1,584 | 396 | $8.63 | $14K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,480 | 15 | $5.97 | $8,839 |
| 99214 Office E&M - Established | Office | 1,148 | 493 | $89.44 | $103K |
| 96413 Chemotherapy Administration | Office | 787 | 89 | $88.08 | $69K |
By year: 2022 $4.9M for 374,503 services; 2023 $4.6M for 272,420 services; 2024 $5.4M for 229,655 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,876 | 547 | $7.60 | $22K |
| 36415 Venipuncture Blood Collection | 1,584 | 396 | $8.63 | $14K |
| 81003 Clinical Chemistry | 64 | 24 | $2.20 | $141 |
Medicare prescription drug claims, 2024
In 2024, the drug Elquis M Castillo prescribed most often to Medicare patients was Letrozole, with 383 prescriptions and refills. In total Elquis M Castillo wrote 4,155 Medicare prescriptions that cost $10.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 383 | 693 | 82 | $6,825 |
| Ondansetron Hcl Generic | 223 | 226 | 138 | $4,740 |
| Prochlorperazine Maleate Generic | 168 | 169 | 116 | $3,064 |
| Oxycodone Hcl Generic | 147 | 147 | 35 | $2,447 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 139 | 139 | 35 | $2,089 |
| Potassium Chloride Generic | 136 | 172 | 43 | $2,086 |
| Tamoxifen Citrate Generic | 136 | 273 | 28 | $3,450 |
| Prednisone Generic | 126 | 145 | 38 | $493 |
| Eliquis Apixaban | 119 | 141 | 28 | $78K |
| Kisqali Ribociclib Succinate | 110 | 110 | 16 | $1.4M |
| Anastrozole Generic | 98 | 214 | 24 | $1,868 |
| Xarelto Rivaroxaban | 96 | 154 | 17 | $84K |
| Hydroxyurea Generic | 92 | 200 | 25 | $2,466 |
| Warfarin Sodium Generic | 87 | 108 | 11 | $460 |
| Levothyroxine Sodium Generic | 81 | 118 | 19 | $1,330 |
Brand drugs: - claims; generic drugs: 3,164 claims; opioid claims: 442.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elquis M Castillo $363 ($363 in general payments such as food, travel and fees) from 2 companies. The largest payer was US Oncology Corporate, Inc. with $229.
| Company | Payments | Amount |
|---|---|---|
| US Oncology Corporate, Inc. | 2 | $229 |
| Intuitive Surgical, Inc. ISRG | 1 | $133 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.